Sava Infond d.o.o. Sells 270 Shares of Amgen Inc. (NASDAQ:AMGN)

Sava Infond d.o.o. cut its stake in Amgen Inc. (NASDAQ:AMGN) by 8.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,830 shares of the medical research company’s stock after selling 270 shares during the quarter. Sava Infond d.o.o.’s holdings in Amgen were worth $882,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of AMGN. Pinney & Scofield Inc. acquired a new position in shares of Amgen in the fourth quarter valued at about $26,000. Ritter Daniher Financial Advisory LLC DE grew its stake in shares of Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 51 shares in the last quarter. Synergy Investment Management LLC acquired a new position in shares of Amgen in the fourth quarter valued at about $34,000. Atala Financial Inc acquired a new position in shares of Amgen in the fourth quarter valued at about $34,000. Finally, Heck Capital Advisors LLC acquired a new position in shares of Amgen in the fourth quarter valued at about $36,000. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on AMGN. Guggenheim began coverage on shares of Amgen in a research note on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 price target on the stock. Wall Street Zen upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 18th. Morgan Stanley reissued an “equal weight” rating on shares of Amgen in a report on Friday, May 2nd. UBS Group reissued a “neutral” rating and issued a $315.00 target price (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Finally, Johnson Rice set a $294.00 target price on shares of Amgen in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $309.22.

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president now owns 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.69% of the stock is owned by company insiders.

Amgen Stock Down 5.8%

Shares of NASDAQ AMGN opened at $272.44 on Tuesday. The company has a 50 day simple moving average of $281.39 and a 200 day simple moving average of $286.10. The firm has a market cap of $146.49 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 2.62 and a beta of 0.51. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.17 and a quick ratio of 0.88.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business earned $3.96 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.